Smart Cancer Drug RK-251 Targets Tumours Without Damaging Healthy Cells
The story in brief
RK-251, a smart cancer drug, is designed to target tumour cells while sparing healthy ones by activating inside cells with high ROS levels, releasing NBDHEX to block cancer survival proteins. It avoids the side effects of conventional chemotherapy, which harms both cancerous and normal cells. The drug's ROS-responsive mechanism was confirmed through fluorescence tests, and zebrafish studies provided early safety signals. Further trials are needed before human use.